Abstract:
The landscape of cell and gene therapies (CGTs) is undergoing a significant transformation, expanding beyond oncology into the treatment of autoimmune diseases. This shift is driven by the success of CAR-T therapies in hematologic malignancies, the growing unmet need in autoimmune disorders, and advancements in immunomodulatory techniques such as regulatory T cells (Tregs) and gene editing technologies like CRISPR. Additionally, regulatory agencies and biopharmaceutical companies are increasingly investing in this field, recognizing its potential for widespread clinical impact.
With over 80 recognized autoimmune diseases affecting millions globally, existing treatments rely on symptom management rather than curative approaches. The application of cell and gene therapies offers a promising new frontier for restoring immune tolerance and achieving long-term remission however, the unique challenges such as disease complexity, immune system risks, scalability, and cost considerations must be carefully navigated.
The successful implementation of CGTs for autoimmune diseases requires an approach that integrates expertise in immunology, genetic and cellular engineering, and regulatory compliance for living therapies. Patient-physician engagement and education are also critical for adoption and accessibility.
This webinar will explore the key drivers behind the transition from oncology to autoimmune and the essential considerations needed to advance CGTs in autoimmune disease treatment. Through case studies and industry insights, this presentation will provide a comprehensive overview of the shift in clinical research priorities and the future of cell and gene therapies in autoimmune disease treatment. Join us as we explore this exciting evolution in regenerative medicine and immunotherapy.
This webinar will appeal to VPs, Directors, Managers and Heads involved in:
- Research and Development (R&D)
- Clinical Project Management/Trial Oversight
- Clinical Operations/Clinical Research
- Medical Affairs/Medical Writing/Pharmacovigilance
- Biostatistics and Data Science
- Regulatory Affairs/Strategy
- Chief Medical Officers (CMOs) and CEOs of small and medium-sized biotech/pharmaceutical companies
In this webinar, attendees will:
- Gain an understanding of the market shift of cell and gene therapies beyond cancer to address autoimmune diseases
- Learn how innovative immunomodulatory techniques are enabling new treatment possibilities
- Discover the key factors needed to successfully develop and deliver CGTs for autoimmune diseases
- Gain insight into how CGTs could transform autoimmune care by offering long-term remission instead of symptom management
Desmond Cabrera — Vice President, Global Head, Cell and Gene Therapy
Desmond Cabrera is a seasoned global operations leader with extensive experience in biotechnology and pharmaceuticals. He specializes in cell and gene therapy and has led clinical trials across multiple therapeutic areas. As VP, Head of Global Operations for a mid-sized global CRO, Desmond oversees global project management teams, financial planning, and milestone delivery. His expertise in multinational team leadership, process optimization, and strategic partnerships consistently drives operational excellence and customer satisfaction. Desmond’s track record in advancing clinical development and executing high-stakes negotiations has been instrumental in achieving corporate goals and ensuring long-term success.
Brian Abbott, MD — Executive Medical Director, Therapeutic Area Medical Lead, Oncology/Hematology
Brian Abbott, MD, is an expert in hematology, oncology, and biomedical research, specializing in clinical trial strategy and medical monitoring. As Executive Medical Director at Allucent, he provides strategic guidance on clinical trials. He previously held leadership roles at ICON plc, Myriad Genetics, and Caris Life Sciences. Before transitioning to research, Dr. Abbott focused on hematologic malignancies, BMT, and medical oncology, serving on the faculty at the University of Colorado and St. Jude Children’s Research Hospital. He holds an MD, MBA, and MS in Finance and is board-certified in Hematology/Oncology, Pediatrics, and Hospice and Palliative Medicine.
Stephanie Stempf — Project Director, Global Project Leadership, Clinical Project Management
Stephanie, a Project Director specializing in Cell and Gene Therapy at Allucent, has over 15 years of clinical research experience. She oversees clinical trials, ensuring client satisfaction, timelines, and budgets while managing technical and operational aspects. Beginning in oncology at the site level, she advanced to clinical trial lead and has worked in project management since 2012. With expertise in 75+ studies across Phases I-III, oncology, immuno-oncology, and advanced therapies, she has extensive PK/PD and tumor tissue collection experience. Previously, she was a Program Manager at Tempus Labs. Stephanie holds a Microbiology degree from Michigan State University.
Share This
